AI주식인사이트AI Stock Insight
C

현대바이오랜드

052260KOSDAQ

48.5 / 100

Reference Date: 2026-09-08

Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 6.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai BioLand operates in various sectors including cosmetics, health supplements, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural bio-materials. The company focuses on developing high-value products such as hyaluronic acid and plant-based collagen, while expanding global partnerships. It emphasizes R&D to meet environmental regulations and consumer trends, and is actively growing its market presence through innovative technologies and strategic collaborations.

Number of Employees

342people

Average Salary

66.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
495.62Industry Average 15.000.0Point

33.0x industry avg (risky)

PBR
0.87Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
0.18Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
1.84Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (36%)

Current 3,965Won52-week high 5,23052-week low 3,225
1-month return4.0Point

1m +6.02% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1
  • Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-28
  • Neutral기업설명회(IR)개최2026-08-26
  • Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
  • Neutral반기보고서 (2026.06)2026-08-14